Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2010

01-07-2010 | Epidemiology

The functional promoter polymorphism (−842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger

Authors: Chan H. Han, Jiachun Lu, Qingyi Wei, Melissa L. Bondy, Abenaa M. Brewster, Tse-Kuan Yu, Thomas A. Buchholz, Banu K. Arun, Li-E Wang

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Login to get access

Abstract

PIN1, an isomerase that causes conformational changes in proteins, plays an important role in mammary epithelial cell growth both physiologically and pathologically. Thus, genetic variants in the PIN1 gene may alter protein function and cancer risk. We have previously demonstrated an association between a PIN1 promoter variant (−842G>C; rs2233678) and risk of squamous cell carcinoma of the head and neck, a finding supported by additional functional data. In the present study, we genotyped two promoter single nucleotide polymorphisms (SNPs) (−842G>C, rs2233678 and −667T>C, rs2233679) and one synonymous SNP (Gln33Gln; G>A, rs2233682) in exon 2 to evaluate their associations with risk of sporadic breast cancer in non-Hispanic white women 55 years and younger. We found that the carriers of −842C variant alleles had decreased risk of breast cancer with an adjusted odd ratio (OR) of 0.67 and 95% confidence interval (CI) of 0.50–0.90. This reduced risk was more evident in women after reproductive age of 45 (OR = 0.63, 95% CI = 0.42–0.93), ever-smokers (OR = 0.56, 95% CI = 0.36–0.88), and ever-drinkers (OR = 0.67, 95% CI = 0.45–0.99). No such associations were observed for PIN1 −667T>C and PIN1 Gln33Gln. However, the haplotypes of these three SNPs were also associated with reduced risk of breast cancer. In conclusion, the PIN1 polymorphisms may contribute to the etiology of sporadic breast cancer in non-Hispanic white women 55 years and younger. Further validation in large population-based studies is needed.
Literature
1.
go back to reference Lu KP, Liou YC, Zhou XZ (2002) Pinning down proline-directed phosphorylation signaling. Trends Cell Biol 12:164–172CrossRefPubMed Lu KP, Liou YC, Zhou XZ (2002) Pinning down proline-directed phosphorylation signaling. Trends Cell Biol 12:164–172CrossRefPubMed
2.
go back to reference Ryo A, Liou YC, Lu KP et al (2003) Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J Cell Sci 116:773–783CrossRefPubMed Ryo A, Liou YC, Lu KP et al (2003) Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J Cell Sci 116:773–783CrossRefPubMed
3.
4.
go back to reference Suizu F, Ryo A, Wulf G et al (2006) Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. Mol Cell Biol 26:1463–1479CrossRefPubMed Suizu F, Ryo A, Wulf G et al (2006) Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. Mol Cell Biol 26:1463–1479CrossRefPubMed
5.
go back to reference Ranganathan R, Lu KP, Hunter T et al (1997) Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 89:875–886CrossRefPubMed Ranganathan R, Lu KP, Hunter T et al (1997) Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 89:875–886CrossRefPubMed
6.
go back to reference Zhou XZ, Lu PJ, Wulf G et al (1999) Phosphorylation-dependent prolyl isomerization: a novel signaling regulatory mechanism. Cell Mol Life Sci 56:788–806CrossRefPubMed Zhou XZ, Lu PJ, Wulf G et al (1999) Phosphorylation-dependent prolyl isomerization: a novel signaling regulatory mechanism. Cell Mol Life Sci 56:788–806CrossRefPubMed
7.
go back to reference Zhou XZ, Kops O, Werner A et al (2000) Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 6:873–883CrossRefPubMed Zhou XZ, Kops O, Werner A et al (2000) Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 6:873–883CrossRefPubMed
8.
go back to reference Stukenberg PT, Kirschner MW (2001) Pin1 acts catalytically to promote a conformational change in Cdc25. Mol Cell 7:1071–1083CrossRefPubMed Stukenberg PT, Kirschner MW (2001) Pin1 acts catalytically to promote a conformational change in Cdc25. Mol Cell 7:1071–1083CrossRefPubMed
9.
go back to reference Shen M, Stukenberg PT, Kirschner MW et al (1998) The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev 12:706–720CrossRefPubMed Shen M, Stukenberg PT, Kirschner MW et al (1998) The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev 12:706–720CrossRefPubMed
10.
go back to reference Lu PJ, Wulf G, Zhou XZ et al (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399:784–788CrossRefPubMed Lu PJ, Wulf G, Zhou XZ et al (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399:784–788CrossRefPubMed
11.
go back to reference Ayala G, Wang D, Wulf G et al (2003) The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 63:6244–6251PubMed Ayala G, Wang D, Wulf G et al (2003) The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 63:6244–6251PubMed
12.
go back to reference Ryo A, Nakamura M, Wulf G et al (2001) Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC Nat. Cell Biol 3:793–801 Ryo A, Nakamura M, Wulf G et al (2001) Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC Nat. Cell Biol 3:793–801
13.
go back to reference Wulf GM, Ryo A, Wulf GG et al (2001) Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20:3459–3472CrossRefPubMed Wulf GM, Ryo A, Wulf GG et al (2001) Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20:3459–3472CrossRefPubMed
14.
go back to reference Lam PB, Burga LN, Wu BP et al (2008) Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer 7:91CrossRefPubMed Lam PB, Burga LN, Wu BP et al (2008) Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer 7:91CrossRefPubMed
15.
go back to reference Liou YC, Ryo A, Huang HK et al (2002) Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci USA 99:1335–1340CrossRefPubMed Liou YC, Ryo A, Huang HK et al (2002) Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci USA 99:1335–1340CrossRefPubMed
16.
go back to reference Segat L, Pontillo A, Annoni G et al (2007) PIN1 promoter polymorphisms are associated with Alzheimer’s disease. Neurobiol Aging 28:69–74CrossRefPubMed Segat L, Pontillo A, Annoni G et al (2007) PIN1 promoter polymorphisms are associated with Alzheimer’s disease. Neurobiol Aging 28:69–74CrossRefPubMed
17.
go back to reference Segat L, Milanese M, Crovella S (2007) Pin1 promoter polymorphisms in hepatocellular carcinoma patients. Gastroenterology 132:2618–2619 author reply 2619–2620CrossRefPubMed Segat L, Milanese M, Crovella S (2007) Pin1 promoter polymorphisms in hepatocellular carcinoma patients. Gastroenterology 132:2618–2619 author reply 2619–2620CrossRefPubMed
18.
go back to reference Lambert JC, Bensemain F, Chapuis J et al (2006) Association study of the PIN1 gene with Alzheimer’s disease. Neurosci Lett 402:259–261CrossRefPubMed Lambert JC, Bensemain F, Chapuis J et al (2006) Association study of the PIN1 gene with Alzheimer’s disease. Neurosci Lett 402:259–261CrossRefPubMed
19.
go back to reference Nowotny P, Bertelsen S, Hinrichs AL et al (2007) Association studies between common variants in prolyl isomerase Pin1 and the risk for late-onset Alzheimer’s disease. Neurosci Lett 419:15–17CrossRefPubMed Nowotny P, Bertelsen S, Hinrichs AL et al (2007) Association studies between common variants in prolyl isomerase Pin1 and the risk for late-onset Alzheimer’s disease. Neurosci Lett 419:15–17CrossRefPubMed
20.
go back to reference Lu J, Hu Z, Wei S et al (2009) A novel functional variant (−842G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis 30:1717–1721CrossRefPubMed Lu J, Hu Z, Wei S et al (2009) A novel functional variant (−842G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis 30:1717–1721CrossRefPubMed
21.
go back to reference Lu J, Wei Q, Bondy ML et al (2006) Promoter polymorphism (−786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107:2245–2253CrossRefPubMed Lu J, Wei Q, Bondy ML et al (2006) Promoter polymorphism (−786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107:2245–2253CrossRefPubMed
22.
go back to reference Lu J, Wei Q, Bondy ML et al (2008) Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged ≤55 years. Breast Cancer Res Treat 110:357–366CrossRefPubMed Lu J, Wei Q, Bondy ML et al (2008) Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged ≤55 years. Breast Cancer Res Treat 110:357–366CrossRefPubMed
23.
go back to reference Lu J, Wei Q, Bondy ML et al (2006) Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women ≤55 years. Carcinogenesis 27:2209–2216CrossRefPubMed Lu J, Wei Q, Bondy ML et al (2006) Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women ≤55 years. Carcinogenesis 27:2209–2216CrossRefPubMed
24.
go back to reference Bao L, Kimzey A, Sauter G et al (2004) Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 164:1727–1737PubMed Bao L, Kimzey A, Sauter G et al (2004) Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 164:1727–1737PubMed
25.
go back to reference Beckmann MW, Niederacher D, Schnurch HG et al (1997) Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 75:429–439CrossRefPubMed Beckmann MW, Niederacher D, Schnurch HG et al (1997) Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 75:429–439CrossRefPubMed
26.
27.
go back to reference Ryo A, Liou YC, Wulf G et al (2002) PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 22:5281–5295CrossRefPubMed Ryo A, Liou YC, Wulf G et al (2002) PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 22:5281–5295CrossRefPubMed
28.
go back to reference MacLachlan TK, Somasundaram K, Sgagias M et al (2000) BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 275:2777–2785CrossRefPubMed MacLachlan TK, Somasundaram K, Sgagias M et al (2000) BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 275:2777–2785CrossRefPubMed
29.
go back to reference Wulf G, Ryo A, Liou YC et al (2003) The prolyl isomerase Pin1 in breast development and cancer. Breast Cancer Res 5:76–82CrossRefPubMed Wulf G, Ryo A, Liou YC et al (2003) The prolyl isomerase Pin1 in breast development and cancer. Breast Cancer Res 5:76–82CrossRefPubMed
30.
go back to reference Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6:229–239CrossRefPubMed Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6:229–239CrossRefPubMed
31.
32.
go back to reference McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321:624–628CrossRefPubMed McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321:624–628CrossRefPubMed
33.
go back to reference Dubik D, Shiu RP (1988) Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263:12705–12708PubMed Dubik D, Shiu RP (1988) Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263:12705–12708PubMed
34.
go back to reference Dubik D, Shiu RP (1992) Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7:1587–1594PubMed Dubik D, Shiu RP (1992) Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7:1587–1594PubMed
35.
go back to reference Lukas J, Bartkova J, Bartek J (1996) Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 16:6917–6925PubMed Lukas J, Bartkova J, Bartek J (1996) Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 16:6917–6925PubMed
36.
go back to reference Wilcken NR, Prall OW, Musgrove EA et al (1997) Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3:849–854PubMed Wilcken NR, Prall OW, Musgrove EA et al (1997) Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3:849–854PubMed
37.
38.
go back to reference Catassi A, Servent D, Paleari L et al (2008) Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res 659:221–231CrossRefPubMed Catassi A, Servent D, Paleari L et al (2008) Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res 659:221–231CrossRefPubMed
40.
go back to reference Ryo A, Wulf G, Lee TH et al (2009) Pinning down HER2-ER crosstalk in SMRT regulation. Trends Biochem Sci 34:162–165CrossRefPubMed Ryo A, Wulf G, Lee TH et al (2009) Pinning down HER2-ER crosstalk in SMRT regulation. Trends Biochem Sci 34:162–165CrossRefPubMed
Metadata
Title
The functional promoter polymorphism (−842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger
Authors
Chan H. Han
Jiachun Lu
Qingyi Wei
Melissa L. Bondy
Abenaa M. Brewster
Tse-Kuan Yu
Thomas A. Buchholz
Banu K. Arun
Li-E Wang
Publication date
01-07-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0682-9

Other articles of this Issue 1/2010

Breast Cancer Research and Treatment 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine